JP2022513700A - 放射性免疫複合体とチェックポイント阻害剤の併用療法 - Google Patents

放射性免疫複合体とチェックポイント阻害剤の併用療法 Download PDF

Info

Publication number
JP2022513700A
JP2022513700A JP2021531492A JP2021531492A JP2022513700A JP 2022513700 A JP2022513700 A JP 2022513700A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2022513700 A JP2022513700 A JP 2022513700A
Authority
JP
Japan
Prior art keywords
tumor
cancer
group
alkyl
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531492A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020115556A5 (https=
JP2022513700A5 (https=
Inventor
エリック スティーブン ブラク，
ジュリー メトカーフ，
ナタリー グリンシュタイン，
メイドゥオ フー，
ジョン フィツモーリス ヴァリアント，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of JP2022513700A publication Critical patent/JP2022513700A/ja
Publication of JPWO2020115556A5 publication Critical patent/JPWO2020115556A5/ja
Publication of JP2022513700A5 publication Critical patent/JP2022513700A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021531492A 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法 Pending JP2022513700A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03
US62/774,847 2018-12-03
PCT/IB2019/001342 WO2020115556A1 (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (3)

Publication Number Publication Date
JP2022513700A true JP2022513700A (ja) 2022-02-09
JPWO2020115556A5 JPWO2020115556A5 (https=) 2023-10-25
JP2022513700A5 JP2022513700A5 (https=) 2023-10-25

Family

ID=70973593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531492A Pending JP2022513700A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Country Status (18)

Country Link
US (5) US20220088231A1 (https=)
EP (2) EP3890789A4 (https=)
JP (3) JP2022513700A (https=)
KR (2) KR20210099073A (https=)
CN (4) CN117482261A (https=)
AU (2) AU2019394888A1 (https=)
BR (2) BR112021010670A2 (https=)
CA (2) CA3119917A1 (https=)
CL (2) CL2021001432A1 (https=)
EA (2) EA202191556A1 (https=)
IL (2) IL283613A (https=)
MA (2) MA54401A (https=)
MX (2) MX2021006408A (https=)
PE (2) PE20211286A1 (https=)
PH (2) PH12021551282A1 (https=)
SG (2) SG11202105112RA (https=)
WO (2) WO2020115548A1 (https=)
ZA (1) ZA202103429B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
CR20210556A (es) 2019-05-10 2021-12-17 Janssen Biotech Inc Quelantes macrocíclicos y métodos de uso de estos
WO2021142231A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Sustained immunotherapy
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US20250275946A1 (en) * 2021-02-02 2025-09-04 Unm Rainforest Innovations Combination therapy for the treatment of cancer
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
CA3233733A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
TW202325344A (zh) * 2021-11-02 2023-07-01 加拿大商融合製藥公司 治療癌症之方法
CA3249955A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Polytherapy based on radiopharmaceuticals targeting NTSR1 and DNA damage response inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180126012A1 (en) * 2016-07-18 2018-05-10 Wisconsin Alumni Research Foundation Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
WO2018110515A1 (ja) * 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018204869A1 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
ES2408704T3 (es) * 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
US7612178B2 (en) * 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
WO2011060233A1 (en) * 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
ES2978177T3 (es) * 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
SI3134127T1 (sl) * 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Konjugati zdravil s protitelesi z visoko stopnjo zdravila
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US10702526B2 (en) * 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
EP3303398A1 (en) * 2015-05-29 2018-04-11 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
ES2875747T3 (es) * 2016-01-11 2021-11-11 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
EP3496707A4 (en) 2016-08-09 2020-03-25 Angimmune, LLC Treatment of cancer using a combination of immunomodulation and check point inhibitors
WO2018038680A1 (en) * 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
KR20190053909A (ko) * 2016-09-16 2019-05-20 바이오노믹스 리미티드 항체와 체크포인트 면역 억제제의 병용 요법
EP3585436A1 (en) * 2017-02-24 2020-01-01 Bayer AS Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
JP2020533002A (ja) * 2017-09-13 2020-11-19 ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． メラニン抗体及びその使用
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
CA3130747A1 (en) * 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180126012A1 (en) * 2016-07-18 2018-05-10 Wisconsin Alumni Research Foundation Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
WO2018110515A1 (ja) * 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018204869A1 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
EP3890789A4 (en) 2022-12-14
CA3119915A1 (en) 2020-06-11
PE20211286A1 (es) 2021-07-19
JP2022511471A (ja) 2022-01-31
PH12021551282A1 (en) 2021-12-06
SG11202105192WA (en) 2021-06-29
US20210290788A1 (en) 2021-09-23
PE20211961A1 (es) 2021-10-04
CN113474014A (zh) 2021-10-01
IL283598A (en) 2021-07-29
MX2021006408A (es) 2021-10-22
WO2020115556A1 (en) 2020-06-11
US20220088230A1 (en) 2022-03-24
MA54399A (fr) 2021-10-13
CN113164632A (zh) 2021-07-23
PH12021551237A1 (en) 2021-11-03
US20230270895A1 (en) 2023-08-31
CN120393061A (zh) 2025-08-01
KR20210099073A (ko) 2021-08-11
AU2019393257A1 (en) 2021-06-03
CL2021001433A1 (es) 2021-12-03
US20210290789A1 (en) 2021-09-23
EA202191556A1 (ru) 2021-10-14
SG11202105112RA (en) 2021-06-29
CN117482261A (zh) 2024-02-02
AU2019394888A1 (en) 2021-06-10
MA54401A (fr) 2021-10-13
ZA202103429B (en) 2023-11-29
MX2021006407A (es) 2021-10-22
WO2020115548A1 (en) 2020-06-11
BR112021010670A2 (pt) 2021-08-24
JP2025013486A (ja) 2025-01-24
BR112021010799A2 (pt) 2021-08-24
EP3890789A1 (en) 2021-10-13
EP3890790A1 (en) 2021-10-13
CA3119917A1 (en) 2020-06-11
US20220088231A1 (en) 2022-03-24
US11446401B2 (en) 2022-09-20
EP3890790A4 (en) 2022-12-14
IL283613A (en) 2021-07-29
CL2021001432A1 (es) 2021-12-17
KR20210099074A (ko) 2021-08-11
EA202191557A1 (ru) 2021-10-14

Similar Documents

Publication Publication Date Title
JP2022513700A (ja) 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP7850455B2 (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
JP7191938B2 (ja) Ｉｇｆ－１ｒモノクローナル抗体及びその使用
JP2020522486A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2020518673A (ja) 二官能性キレートの薬物動態増強及びその使用
EP4501363A1 (en) B7h4 antibody-drug conjugate and use thereof
CN110997725A (zh) 抗-il1rap抗体和抗体药物缀合物
US20250121104A1 (en) Egfr-cmet-targeted compounds and uses thereof
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
KR20240021227A (ko) 방사성면역접합체와 체크포인트 억제제의 조합 요법
JP2023510309A (ja) 持続的免疫療法
JP2023518818A (ja) Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用
HK40058366A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
HK40109328A (zh) 放射免疫缀合物及检查点抑制剂组合疗法
HK40060346A (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
HK40118862A (zh) 抗-il1rap抗体和抗体药物缀合物
HK40118654A (en) B7h4 antibody-drug conjugate and use thereof
EA052527B1 (ru) Конъюгат лекарственное средство-антитело к b7h4 и его применение
HK40072804A (en) Antibody-drug conjugates targeting claudin 18.2
HK40072804B (en) Antibody-drug conjugates targeting claudin 18.2
HK40027179B (zh) 抗-il1rap抗体和抗体药物缀合物
HK40027179A (en) Anti-il1rap antibodies and antibody drug conjugates

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240919